Nectar LifesciencesNECLIFE 
-2.78%24h
Nectar Lifesciences (NECLIFE) Stock Overview
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company's active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company provides menthol and mint derivatives and empty hard gelatin capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.
NECLIFE Stock Information
Nectar Lifesciences (NECLIFE) Price Chart
Nectar Lifesciences Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $0.6249027687293505 | N/A |
| Market Cap | $140.14M | N/A |
| Shares Outstanding | 224.26M | 0.00% |
| Employees | 1.59K | N/A |
| Shareholder Equity | 10.65B | -2.14% |
Valuation | 2023 | Change |
|---|---|---|
| P/E Ratio | -0.58 | N/A |
| P/S Ratio | 0.77 | N/A |
| P/B Ratio | 0.01 | N/A |
Growth | 2023 | Change |
|---|---|---|
| Return on Equity | -0.0003 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $181.64M | N/A |
| Earnings | -$2.88M | N/A |
| EPS | -1.08 | N/A |
| Earnings Yield | -1.73 | N/A |
| Gross Margin | 0.1262 | N/A |
| Operating Margin | -0.0034 | N/A |
| Net income margin | -0.0159 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $260.98M | N/A |
| Total Debt | $89.86M | N/A |
| Cash on Hand | $2.13M | N/A |
| Debt to Equity | 0.0126 | -11.80% |
| Cash to Debt | 0.0237 | 11.77% |
| Current Ratio | $1.38 | 2.39% |
